

Project Progress Report: Al Agent for Acute Lymphoblastic Leukemia Diagnosis

Nexus

Supervisor: Ms. Kushani Bandara

Group: 21 Cluster: 21.1


Members:

MJM.Amajith 721434768 MN.Fathima Rafaha 121428697 MMZ. Zahra 221445832

MHA. Ahmed 321422851

Introduction + Background

Acute Lymphoblastic Leukemia (ALL) is a type of cancer that affects the blood and bone marrow. It primarily occurs in children but can also affect adults. ALL is characterized by the uncontrolled growth of lymphoid cells, which are responsible for producing white blood cells.



The diagnosis of ALL is a complex and challenging process that requires careful examination of blood and bone marrow samples. Traditionally, this diagnosis has relied on the expertise of skilled hematopathologists who visually inspect and classify cells under a microscope. However, this manual approach is time-consuming, subjective, and can be prone to human error.

With recent advancements in artificial intelligence (AI) and machine learning, there is a tremendous opportunity to enhance the accuracy and efficiency of ALL diagnosis. By leveraging AI algorithms, we can develop a sophisticated AI agent that can assist medical professionals in accurately identifying and classifying leukemia cells.


The primary objective of this project is to develop an AI agent capable of accurately diagnosing Acute Lymphoblastic Leukemia. By leveraging deep learning techniques and analyzing a large dataset of leukemia samples, the AI agent will learn to identify and classify abnormal cells with a high degree of accuracy.

Through this project, we aim to bridge the gap between medical expertise and cutting-edge Al technology, ultimately enhancing the accuracy, speed, and objectivity of Acute Lymphoblastic Leukemia diagnosis. By combining the power of Al with the knowledge and experience of medical professionals, we can make significant strides in improving leukemia diagnosis and contribute to advancements in cancer care.

In the following sections of this proposal, we will delve into the existing systems for leukemia diagnosis, our proposed solution using an AI agent, the technologies we plan to utilize, and the project timeline. By the end of this endeavor, we anticipate the development of a robust AI agent that will have a transformative impact on Acute Lymphoblastic Leukemia diagnosis.

Problem Statement

Acute Lymphoblastic Leukemia (ALL) diagnosis is a complex and time-consuming process that relies heavily on the expertise of hematopathologists. The traditional manual examination of blood and bone marrow samples for ALL diagnosis is subjective and prone to human error. This approach often leads to delayed diagnosis and potential misclassification of leukemia cells, impacting patient outcomes.



Project Objectives

The primary objective of this project is to develop an AI agent capable of accurately diagnosing Acute Lymphoblastic Leukemia. The AI agent will leverage deep learning techniques to analyze a large dataset of leukemia samples and identify abnormal cells with a high degree of accuracy. By automating the diagnosis process, the project aims to address the following objectives:

- Improve Accuracy: The AI agent will be trained to recognize subtle patterns and
 features in leukemia cells that may not be easily detectable by human observers. By
 leveraging the power of AI algorithms, the project aims to enhance the accuracy of ALL
 diagnosis, leading to more reliable and consistent results.
- Increase Efficiency: The current manual process of leukemia diagnosis is time-consuming and labor-intensive. By developing an AI agent that can quickly analyze and classify leukemia cells, the project aims to significantly reduce the time required for diagnosis, allowing healthcare professionals to make timely treatment decisions.
- Assist Medical Professionals: The AI agent will serve as a supportive tool for hematopathologists, augmenting their expertise and providing them with additional insights during the diagnostic process. By assisting in the identification and classification of leukemia cells, the project aims to enhance the capabilities of medical professionals in making accurate and informed diagnoses.
- Enhance Patient Outcomes: Early and accurate diagnosis of Acute Lymphoblastic Leukemia is crucial for developing appropriate treatment plans and improving patient outcomes. By developing an Al agent that can aid in early detection and diagnosis, the project aims to contribute to better patient care and potentially save lives.

By achieving these project objectives, we aim to revolutionize the field of leukemia diagnosis by combining the power of AI with the expertise of medical professionals. The proposed AI agent has the potential to significantly impact the accuracy, efficiency, and effectiveness of Acute Lymphoblastic Leukemia diagnosis, ultimately leading to improved patient outcomes.

Introduction to Similar Type of Applications

In the real world, there are several implemented computer applications that utilize artificial intelligence (AI) techniques for the diagnosis of various diseases, including cancer. These applications have made significant advancements in improving diagnostic accuracy and assisting healthcare professionals in their decision-making process. Some examples of implemented AI applications in the medical field are:

 Aidoc: Aidoc is an Al-powered radiology platform that focuses on detecting abnormalities in medical imaging scans. It employs deep learning algorithms to analyze computed tomography (CT) scans and flag potential abnormalities, aiding radiologists in the diagnosis of conditions such as intracranial hemorrhage, pulmonary embolism, and cervical spine fractures.



 Tempus: Tempus is an Al-based healthcare platform that integrates molecular data, clinical data, and imaging data to provide personalized treatment options for cancer patients. It utilizes machine learning algorithms to analyze large datasets and identify patterns that can inform treatment decisions and improve patient outcomes.



 Proscia: Proscia is a digital pathology company that applies AI algorithms to digitized histopathology slides. Their platform, Concentriq, enables pathologists to analyze and interpret slides more efficiently and accurately. By automating routine tasks and assisting in the identification of cancerous cells, Proscia's AI-powered solution enhances the speed and accuracy of pathology diagnosis.

These implemented AI applications in the medical field demonstrate the potential and benefits of using AI for disease diagnosis. While not specific to Acute Lymphoblastic Leukemia (ALL), they showcase the successful integration of AI into medical practice and provide valuable insights for developing a similar AI agent for ALL diagnosis.

By leveraging the advancements made in these implemented applications, we aim to create an effective and reliable AI agent tailored specifically for the diagnosis of Acute Lymphoblastic Leukemia. This agent will utilize AI algorithms, deep learning techniques, and domain-specific data to enhance the accuracy and efficiency of ALL diagnosis, contributing to improved patient care and outcomes.

Proposed Solution

This project aims to develop an AI agent that will significantly improve the accuracy and efficiency of diagnosing Acute Lymphoblastic Leukemia (ALL). This AI agent will leverage advanced machine learning techniques and domain-specific knowledge to analyze leukemia cells and assist hematopathologists in their diagnostic process.

Automated Cell Analysis

The AI agent will employ computer vision algorithms to automatically analyze leukemia cells from blood and bone marrow samples. It will utilize deep learning techniques, such as convolutional neural networks (CNNs), to extract meaningful features and patterns from the cell images. By analyzing these features, the AI agent will be able to differentiate between normal and abnormal cells, specifically those associated with ALL.

Enhanced Accuracy and Efficiency

The AI agent will significantly enhance the accuracy of ALL diagnosis by leveraging its ability to analyze large quantities of cells quickly and accurately. It will reduce the potential for human error and variability in manual analysis, leading to more reliable and consistent results. Moreover, the AI agent's efficiency will allow hematopathologists to process a higher volume of samples in less time, leading to faster diagnosis and treatment decisions.

Integration of Clinical Data

In addition to cell analysis, the AI agent will integrate relevant clinical data into the diagnostic process. It will consider patient information, such as age, gender, medical history, and laboratory test results, to provide a comprehensive assessment of ALL. By combining cell analysis with clinical data, the AI agent will offer a holistic approach to diagnosis, enabling hematopathologists to make more informed decisions.

Interpretability and Explainability

To build trust and facilitate collaboration between the AI agent and hematopathologists, the proposed solution will prioritize interpretability and explainability. The AI agent will provide explanations and visualizations of its analysis, highlighting the key features and patterns that contribute to its diagnostic decisions. This transparency will enable hematopathologists to understand and validate the agent's reasoning, fostering trust and confidence in its capabilities.

Clinical Integration and Validation

The proposed AI agent will undergo rigorous validation and integration into clinical workflows. It will be tested on a large and diverse dataset, consisting of samples from different populations and healthcare settings. The performance of the AI agent will be compared against the diagnoses made by expert hematopathologists to validate its accuracy and reliability.

Technology Planning to Use

In this section, we will discuss the backend and frontend technologies that are planned to be used in the development of the AI agent for Acute Lymphoblastic Leukemia (ALL) diagnosis.

Backend Technologies

For the backend development, the project will utilize Django, a high-level Python web framework. Django provides a robust and efficient framework for handling user authentication, database management, and server-side logic. It offers various features such as an Object-Relational Mapper (ORM), URL routing, and templating system, which will simplify the development process and enhance the scalability of the application. In terms of the database management system, MySQL will be employed as the backend database for storing the necessary data, including user information, patient records, and training data. MySQL is a widely used and reliable relational database management system that offers excellent performance and scalability.

Additionally, Django provides seamless integration with MySQL through its built-in support for different database backends, allowing efficient data retrieval and manipulation.

Frontend Technologies

For the frontend development, a combination of HTML, CSS, and JavaScript will be used to create an intuitive and user-friendly interface. HTML (Hypertext Markup Language) will be used for structuring the webpages, while CSS (Cascading Style Sheets) will be used for styling and layout. To enhance the interactivity and user experience, JavaScript, along with popular frameworks such as React or Vue.js, can be utilized. These frameworks provide powerful tools for building dynamic and responsive web interfaces, allowing seamless communication with the backend and providing real-time updates.

Additionally, frontend design tools such as Adobe XD, Figma, or Sketch can be used to create mockups and design prototypes, ensuring a visually appealing and user-friendly interface.

TensorFlow for Model Training

For the model training phase, TensorFlow, an open-source machine learning framework, will be used. TensorFlow provides a comprehensive ecosystem of tools, libraries, and resources for developing and training deep learning models. With TensorFlow, you can efficiently build and train neural network models for image classification, including convolutional neural networks (CNNs) tailored for analyzing leukemia cells. TensorFlow offers extensive documentation, pre-trained models, and utilities for data preprocessing and model evaluation, making it a suitable choice for developing the Al agent.

Project Progress

The following milestones have been achieved:

- Dependencies for initial implementation were installed.
- The SRS was finalized.
- The project progress review presentation was finalized.
- A project progress review report was created.
- The dataset preprocessing stage was completed.

The next steps for the project are to:

- Train the machine learning model.
- Evaluate the performance of the model.
- Implement backend features.
- Implement frontend features.
- Seek client's approval on each spring.

We are confident that the project will be completed on time. We are excited to see how this application can help to improve the diagnosis and treatment of Acute Lymphoblastic Leukemia.

Here are some additional details about each milestone:

- Dependencies for initial implementation were installed: This involved installing the necessary software and libraries to get the project started.
- The SRS was finalized: The SRS is a document that describes the requirements for the project. It was finalized after careful consideration of the needs of the project stakeholders.
- The project progress review presentation was finalized: This presentation was given to the project stakeholders to update them on the progress of the project.
- A project progress review report was created: This report documented the progress of the project in more detail.
- The dataset preprocessing stage was completed: This involved cleaning and preparing the dataset of pathological cell images for use in training the machine learning model.

Project Timeline

The following timeline outlines the estimated duration for each phase of the project




Figure 1: Gantt Chart

Please note that the timeline provided is an estimate and may be subject to change based on project requirements, resource availability, and unforeseen challenges that may arise during the development process.

Conclusion

In conclusion, this report has presented a project proposal for developing an Al agent for Acute Lymphoblastic Leukemia (ALL) diagnosis. The proposed solution aims to leverage advanced machine learning techniques, including deep learning and computer vision, to automate cell analysis, enhance accuracy and efficiency, integrate clinical data, and enable continuous learning.


The project will utilize Django as the backend framework, MySQL as the database management system, and TensorFlow for model training. The frontend development will involve HTML, CSS, and JavaScript, with possible integration of frameworks such as React or Vue.js for enhanced interactivity.

A comprehensive project timeline has been provided, outlining the expected durations for each phase, including requirement engineering, implementation, model design and training, and finalizing. However, it is important to note that timelines are subject to adjustments based on project-specific considerations and unforeseen circumstances.


Thank you for considering this project proposal. We believe that with the planned approach, technologies, and timeline, we can successfully develop and deploy an effective AI agent for ALL diagnosis.

Appendix

High-level Use-case Diagram




Proposed Technical Solution




References

- Acute lymphoblastic leukemia (Wikipedia)
- In Childhood Acute Lymphoblastic Leukemia, Blasts at Different Stages of Immunophenotypic Maturation Have Stem Cell Properties (cell.com)
- An Intelligent Decision Support System for Leukaemia Diagnosis using Microscopic Blood Images (nature.com)
- Leukemia Classification (kaggle.com)
- Software Requirements Specification (Added)
- Project Progress Presentation (Added)
- CMMI Meeting Mins (Added)
- Monthly Retrospective



• Git



- Trello (Project Governance Tool)

